Loss of S100 antigenicity in metastatic melanoma

Human Pathology

Volumn 36, Issue 9, 2005, Pages 1016-1019

  Aisner, Dara L ^a   Maker, Ajay ^a   Rosenberg, Steven A ^a   Berman, David M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antigenicity; Diagnosis; Melanoma; S100

Indexed keywords

GLYCOPROTEIN GP 100; MELAN A; PROTEIN S 100;

ANTIGENICITY; ARTICLE; CANCER LOCALIZATION; CANCER SURGERY; CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; EYE CANCER; HEALTH CARE ORGANIZATION; HEALTH STATUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOMA; MEDICAL DOCUMENTATION; MELANOMA; PROTEIN ANALYSIS; SARCOMA; SKIN METASTASIS; TIME;

EYE NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; MELANOMA; NEOPLASM METASTASIS; S100 PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 24344439755     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2005.07.010     Document Type: Article

References (23)

1. T.J. de Vries, M. Smeets, R. de Graaf, K. Hou-Jensen, E.B. Brocker, and N. Renard Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group J Pathol 193 2001 13 20
2. D.J. Karimipour, L. Lowe, L. Su, T. Hamilton, V. Sondak, and T.M. Johnson Standard immunostains for melanoma in sentinel lymph node specimens: which ones are most useful? J Am Acad Dermatol 50 2004 759 764
3. O. Kaufmann, S. Koch, J. Burghardt, H. Audring, and M. Dietel Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections Mod Pathol 11 1998 740 746
4. J. Mangini, N. Li, and J. Bhawan Immunohistochemical markers of melanocytic lesions: a review of their diagnostic usefulness Am J Dermatopathol 24 2002 270 281
5. P. Kocan, I. Jurkovic, A. Boor, K. Dudrikova, R. Krajcar, and M. Benicky Immunohistochemical study of malanocytic differentiation antigens in cutaneous malignant melanoma. A comparison of six commercial antibodies and one non-commercial antibody in nodular melanoma, superficially spreading melanoma and lentigo maligna melanoma Cesk Patol 40 2004 50 56
6. J. Zubovits, E. Buzney, L. Yu, and L.M. Duncan HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma Hum Pathol 35 2004 217 223
7. S.S. Banerjee, and M. Harris Morphological and immunophenotypic variations in malignant melanoma Histopathology 36 2000 387 402
8. P.W. Bishop, L.P. Menasce, A.J. Yates, N.A. Win, and S.S. Banerjee An immunophenotypic survey of malignant melanomas Histopathology 23 1993 159 166
9. Z.B. Argenyi, C. Cain, C. Bromley, A.V. Nguyen, A.A. Abraham, and R. Kerschmann S-100 protein-negative malignant melanoma: fact or fiction? A light-microscopic and immunohistochemical study Am J Dermatopathol 16 1994 233 240
10. D.B. Zimmer, E.H. Cornwall, A. Landar, and W. Song The S100 protein family: history, function, and expression Brain Res Bull 37 1995 417 429
11. I. Marenholz, C.W. Heizmann, and G. Fritz S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature) Biochem Biophys Res Commun 322 2004 1111 1122
12. W.Y. Lee, W.C. Su, P.W. Lin, H.R. Guo, T.W. Chang, and H.H. Chen Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer Oncology 66 2004 429 438
13. R. Harpio, and R. Einarsson S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma Clin Biochem 37 2004 512 518
14. S. Diederichs, E. Bulk, B. Steffen, P. Ji, L. Tickenbrock, and K. Lang S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer Cancer Res 64 2004 5564 5569
15. J. Lin, Q. Yang, Z. Yan, J. Markowitz, P.T. Wilder, and F. Carrier Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells J Biol Chem 279 2004 34071 34077
16. J. Timar, N. Udvarhelyi, T. Banfalvi, K. Gilde, and Z. Orosz Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies Histopathology 44 2004 180 184
17. M.T. Spiotto, D.A. Rowley, and H. Schreiber Bystanders elimination of antigen loss variants in established tumors Nat Med 10 2004 294 298
18. L. Sanchez-Perez, T. Kottke, R.M. Diaz, A. Ahmed, J. Thompson, and H. Chong Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo Cancer Res 65 2005 2009 2017
19. I. Papadopoulos, E. Sivridis, A. Giatromanolaki, and M.I. Koukourakis Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer Clin Cancer Res 7 2001 1533 1538
20. A.F. Ochsenbein Principles of tumor immunosurveillance and implications for immunotherapy Cancer Gene Ther 9 2002 1043 1055
21. H.T. Khong, Q.J. Wang, and S.A Rosenberg Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression J Immunother 27 2004 184 190
22. M. Ahmad, R.C. Rees, and S.A. Ali Escape from immunotherapy: possible mechanisms that influence tumor regression/progression Cancer Immunol Immunother 53 2004 844 854
23. J. Kan-Mitchell, N. Rao, D.M. Albert, L.J. Van Eldik, and C.R. Taylor S100 immunophenotypes of uveal melanomas Invest Ophthalmol Vis Sci 31 1990 1492 1496